智通财经APP获悉，1月20日，中国国家药监局药品审评中心(CDE)官网最新公示，赛诺菲(SNY.US)申报的1类新药SAR444656获得临床试验默示许可，拟开发适应症包括特应性皮炎(AD)、化脓性汗腺炎(HS)。

截图来源：CDE官网

公开资料显示，KT-474(SAR444656)是一款IRAK4蛋白降解剂，由Kymera Therapeutics和赛诺菲共同开发。该产品曾被猎药人网站(drughunter.com)列入2023年度十大“明星”小分子。此外，赛诺菲曾在2023年的研发日上介绍其管线中具有重磅潜力的新药名单，其中就包括这款SAR444656。

根据ClinicalTrials官网，赛诺菲正在开展两项国际多中心2期临床研究，分别评估SAR444656治疗中度至重度化脓性汗腺炎成人患者、中度至重度特应性皮炎成人患者的疗效和安全性。本次SAR444656在中国获批临床，意味着该产品也将在中国进入临床研究阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.